In institutional private equity, equity co-investment arrangements are pitched as a win-win. For main fund sponsors (GPs), co-investment syndicates provide additional non-fee-paying capital to secure larger deals without breaching single-asset concentration limits. For limited partners (LPs) and institutional co-investors, they offer direct exposure to choice assets with reduced fee and carry burdens.
However, when exit timetables slip, valuations soften, or a portfolio company requires emergency follow-on capital, the commercial alignment between sponsor and syndicate rapidly unravels.
Co-investors frequently rely on their Shareholders’ Agreement (SHA) or Co-Investment Agreement as a primary safeguard. Yet, in practice, standard co-investment documentation rarely anticipates the actual point of breakdown: the lead sponsor prioritising the return profile, liquidity timing, or fund lifecycle of its flagship fund over the interests of the syndicate.
Understanding where true legal and commercial leverage lies requires looking past headline drag-along rights and examining conflict mechanics, information rights, and the statutory overlay of shareholder oppression under the Corporations Act 2001 (Cth).
This article focuses on co-investment vehicles structured as Australian companies. Where the vehicle is instead a unit trust, the statutory oppression remedy is unavailable and investors must rely on the trust deed, equitable remedies, or (in limited cases) the managed investment scheme provisions, a distinct topic warranting separate treatment.
1. Where the Friction Begins: Exit, Conflicts, and Dilution
Co-investor disputes rarely stem from operational underperformance alone; they arise when the sponsor and the syndicate face divergent commercial incentives during critical corporate events:
The Preferred Exit Dilemma:
A lead sponsor managing a fund near the end of its 10-year term may be under intense pressure to realise an asset to generate liquidity or demonstrate performance for a new fundraise. Conversely, syndicate co-investors, unburdened by the same fund lifecycle constraints, may prefer to hold for a market recovery.
Dual-Hatting and Portfolio Sales:
Sponsors often hold portfolio companies across multiple vehicles, or sell asset packages where a syndicate company is bundled with other portfolio holdings. When the sponsor determines allocation of transaction value or fee structures across a bundled exit, severe conflict issues arise.Pay-to-Play and Creeping Dilution:
During down-rounds or recapitalisations, a sponsor may propose follow-on equity injections on terms that heavily penalise non-participating co-investors. If the syndicate lacks the liquidity or internal approvals to participate, their equity stake faces aggressive dilution.
2. Do Co-Investors or Sponsors Owe Duties to Each Other?
A fundamental misconception among syndicate investors is that the lead sponsor owes them general fiduciary obligations akin to a trustee or general partner handling main fund LP assets.
Under Australian law, the baseline position is clear:
Arm’s-Length Shareholders Do Not Owe Fiduciary Duties:
Pure commercial equity holders in a company do not, by virtue of that relationship alone, owe fiduciary duties of loyalty or good faith to one another. A narrow exception may arise where the relationship between shareholders exhibits the characteristics of a quasi-partnership or a relationship of trust and confidence (see United Dominions Corporation Ltd v Brian Pty Ltd (1985) 157 CLR 1; cf Ebrahimi v Westbourne Galleries Ltd [1973] AC 360), but this is unlikely to be established in an institutional co-investment context governed by detailed contractual documentation.
Contractual Disclaimers Hold Weight:
Modern PE co-investment documentation explicitly disclaims fiduciary relationships, confirming that the sponsor acts purely in its own commercial self-interest subject only to express contractual obligations.
Director Duties Sit at the Holding Board Level:
Directors nominated by the PE sponsor to the holding company board owe statutory and fiduciary duties under sections 180–183 of the Corporations Act 2001 (Cth) to the company as a whole, not to the sponsor fund that appointed them, nor to the syndicate. When a nominee director votes to approve a recapitalisation or sale that favours the sponsor’s fund at the expense of co-investors, that director faces immediate legal exposure for failing to act for a proper purpose or improperly using their position.
3. Contractual Leverage: Look Beyond Headline Economics
When a dispute brews, co-investors usually look to their Drag-Along and Tag-Along clauses. However, these headline exit mechanics are almost exclusively drafted in favour of the sponsor, allowing the lead GP to compel co-investors to sell on the same financial terms.
The genuine contractual leverage for co-investors sits in less obvious, procedural provisions:
Information and Audit Rights:
Sponsors frequently attempt to starve syndicate members of real-time financial reporting during distressed restructuring or exit negotiations. Enforcing express contractual information rights (or exercising statutory inspection rights under section 247A of the Corporations Act) is often the primary tool to uncover valuation misallocations or conflict-ridden exit processes. However, co-investors should note that an application under section 247A requires the applicant to demonstrate good faith and a proper purpose for the inspection, it is not an automatic entitlement and the court retains discretion to refuse or limit access.Consent Rights & Reserved Matters:
Well-structured co-investment agreements include negative covenants requiring syndicate consent for related-party transactions, capital structure alterations, or non-pro-rata equity issuances. Where a sponsor attempts to circumvent these consent gates, interlocutory injunction relief becomes available.Conflict of Interest Protocols:
Where the agreement obliges the sponsor to follow specific conflict resolution mechanisms (such as independent valuation or advisory committee sign-off) prior to a related-party deal or restructuring, a failure by the sponsor to strictly adhere to those steps creates an immediate breach of contract claim.
4. The Statutory Shield: Section 232 Oppression
Where the co-investment vehicle is structured as an Australian proprietary company (Pty Ltd) or public unlisted company, statutory remedies override contractual disclaimers.
Under Section 232 of the Corporations Act 2001 (Cth), the Court may grant relief if the conduct of a company’s affairs, or an actual or proposed act or omission by or on behalf of a company, or a resolution or proposed resolution of members, is either:
- Contrary to the interests of the members as a whole; or
- Oppressive to, unfairly prejudicial to, or unfairly discriminatory against, a member or members whether in that capacity or in any other capacity.
In private equity co-investments, section 232 is a potent weapon for minority syndicate members facing sponsor overreach.
How Oppression Applies to PE Co-Investments
The test for oppression is objective. As the High Court held in Wayde v NSW Rugby League Ltd (1985) 180 CLR 459, the court asks whether the conduct complained of is so unfair that reasonable directors exercising their powers in accordance with their duties would not have engaged in it. The inquiry focuses on whether there has been a visible departure from the standards of fair dealing and a violation of the conditions of fair play that a shareholder is entitled to expect (adopting the formulation from Scottish Co-operative Wholesale Society Ltd v Meyer [1959] AC 324, as applied in Australian oppression jurisprudence).
In the context of PE co-investment disputes, grounds for oppression commonly include:
- Squeeze-Outs and Restructuring at Undervalue: Issuing new equity to the sponsor’s main fund at a distressed valuation without affording co-investors a fair or genuine opportunity to participate, effectively wiping out syndicate equity.
- Improper Valuation Allocation in Package Sales: Allocating sale proceeds preferentially to assets wholly owned by the main fund while under-valuing the asset in which the syndicate holds equity.
- Governance Exclusions: Completely excluding syndicate board observers or representatives from key transaction discussions or material financial updates leading up to a liquidity event.
Importantly, section 233 gives Australian courts broad discretion to grant remedies, including ordering the sponsor to buy out the syndicate’s shares at a fair, un-discounted valuation, setting aside oppressive board resolutions, or enjoining proposed transactions.
5. Strategic Takeaways for PE Sponsors and Co-Investors
Perspective | Key Strategic Priorities |
For Syndicate Co-Investors | • Audit conflict mechanics early: Do not rely on tag-along rights. Ensure pre-negotiated information access and explicit consent gates for related-party capital raises. • Identify nominee director exposure: Remind sponsor-appointed directors of their personal, un-delegable statutory duties to the company when voting on exit allocation or recapitalisations. • Deploy Section 232 early: Where a sponsor uses information opacity to push through an unfair restructuring, raise statutory oppression claims prior to execution. |
For Lead PE Sponsors | • Maintain strict conflict protocols: Utilise independent valuations or external fairness opinions when executing package exits or follow-on fundings involving main fund participation. • Ensure formal board governance: Document nominee director decision-making clearly, demonstrating that decisions were made in the best interests of the target company, not merely the flagship fund. • Manage information flows: Avoid creating grounds for section 247A inspection applications or oppression claims by maintaining transparent communication throughout the exit runway. |
Co-investment disputes demand early, strategic intervention. Whether you are a syndicate investor facing sponsor overreach or a lead GP seeking to manage conflict risk proactively, understanding the interplay between contractual mechanisms, director duties, and statutory remedies is critical to protecting your position. Ironbridge Legal advises both sponsors and co-investors across the full spectrum of PE co-investment disputes.
Further Information
For further information about private equity co-investor disputes, shareholder oppression, sponsor conflicts and exit or recapitalisation disputes, please contact the author of this article:
